Literature DB >> 3813614

Diabetes insipidus and occult intracranial tumours.

M C Sherwood, R Stanhope, M A Preece, D B Grant.   

Abstract

We describe four patients with intracranial tumours who presented with diabetes insipidus and subsequently developed an evolving anterior pituitary endocrinopathy. The delay in imaging the tumours varied between 2.1 and 11.2 years (mean 5.4 years).

Entities:  

Mesh：

Year:  1986        PMID： 3813614      PMCID： PMC1778218          DOI： 10.1136/adc.61.12.1222

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  5 in total

1.  Familial diabetes insipidus.

Authors:  F I MARTIN
Journal:  Q J Med       Date:  1959-10

2.  Hypoplastic optic nerves and pituitary dysfunction. A spectrum of anatomical and endocrine abnormalities.

Authors:  R Stanhope; M A Preece; C G Brook
Journal:  Arch Dis Child       Date:  1984-02       Impact factor: 3.791

3.  High resolution CT scanning of the pituitary gland in growth disorders.

Authors:  R Stanhope; P Hindmarsh; B Kendall; C G Brook
Journal:  Acta Paediatr Scand       Date:  1986-09

4.  [ADH-deficient diabetes insipidus in children. A study of 93 cases (author's transl)].

Authors:  R Pomarède; P Czernichow; R Rappaport; P Royer
Journal:  Arch Fr Pediatr       Date:  1980-01

5.  Evolving hypopituitarism in children with central nervous system lesions.

Authors:  C E Hanna; S H LaFranchi
Journal:  Pediatrics       Date:  1983-07       Impact factor: 7.124
  5 in total
  2 in total

1.  Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom.

Authors:  C R Buchanan; M A Preece; R D Milner
Journal:  BMJ       Date:  1991-04-06

2.  Central Diabetes Insipidus in Children and Adolescents: Twenty-Six Year Experience from a Single Centre.

Authors:  Hüseyin Anil Korkmaz; Ritika R Kapoor; Jennifer Kalitsi; Simon Jb Aylwin; Charles R Buchanan; Ved Bhushan Arya
Journal:  Int J Endocrinol       Date:  2022-03-08       Impact factor: 3.257
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.